logo-loader

Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor

Published: 21:46 05 Jun 2019 AEST

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.

Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

ImmuPharma chairman more optimistic on results for its Lupuzor drug

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive that there is a strong indication that in certain populations of lupus patients, its Lupuzor drug works very effectively.  McCarthy was talking after a deeper dive into the data generated by its phase III clinical trial of...

on 30/5/18